Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12996126 | 0.88 | POLB (0.39) | MEN1KMT2APOLBMAPK1PI4KA | |
| SCHEMBL24415145 | 0.86 | POLB (0.42) | MEN1KMT2APOLBMAPK1PI4KA | |
| SCHEMBL14752201 | 0.82 | KDM4E (0.37) | MEN1KMT2APOLBMAPK1SMN1; SMN2 | |
| SCHEMBL22273345 | 0.75 | MEN1 (0.41) | MEN1KMT2APOLBHSD11B1MAPK1 | |
| SCHEMBL22330447 | 0.75 | MEN1 (0.41) | MEN1KMT2APOLBHSD11B1MAPK1 | |
| SCHEMBL24656125 | 0.75 | MEN1 (0.35) | MEN1KMT2APOLBMAPK1PI4KA | |
| SCHEMBL13377049 | 0.74 | SMN1; SMN2 (0.45) | MEN1KMT2APOLBMAPK1SMN1; SMN2 | |
| SCHEMBL25632367 | 0.73 | MEN1 (0.36) | MEN1KMT2APOLBMAPK1PI4KA | |
| SCHEMBL13377083 | 0.73 | ALDH1A1 (0.47) | MEN1KMT2APOLBMAPK1SMN1; SMN2 | |
| SCHEMBL13377169 | 0.71 | MEN1 (0.43) | MEN1KMT2APOLBMAPK1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675847-B1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2022-04-14 | — | — | US | disclosed |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-10-12 | — | — | US | disclosed |
| US-20200255427-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255427-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | MEN1 2363/4885KMT2A 4253/4885POLB 2503/4885 |
| US-20220110933-A1 | METHODS OF TREATING DISEASE WITH MAGL INHIBITORS | MGLL, LIPA, PNLIP | MEN1 1486/4885KMT2A 2542/4885POLB 1541/4885 |
| US-11142526-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, OPRK1 | MEN1 2363/4885KMT2A 4253/4885POLB 2503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.